Teva and Samsung Bioepis Enter Into Licensing Agreement to Commercialize Etanercept and Infliximab Biosimilars in the U.S.
Big Molecule WatchTopic alignment 85
Cut through the noise, find the signal: Intelligence for serious healthcare leaders
Biosimilar approvals, uptake, pricing and interchangeability
Big Molecule WatchTopic alignment 85
BioPharma DiveTopic alignment 92
A patent cliff is fast approaching for Merck’s flagship blockbuster, but the deck might be stacked against its biosimilars gaining widespread traction.
Big Molecule WatchTopic alignment 90
The Center for BiosimilarsTopic alignment 88
Juliana Reed, MS, of the Biosimilars Forum explains how a proposed bill would define "high likelihood" and delay Medicare negotiation for biologics.
PharmExec (Pharmaceutical Executive)Topic alignment 90
Endpoints NewsTopic alignment 88
WuXi Biologics and German drugmaker Fresenius have reached one of the largest biosimilar deals to date ahead of what some in the industry have called an upcoming “golden decade” for such products. ...